Faculty Opinions recommendation of N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.

2009 ◽  
Author(s):  
Peter Falkai ◽  
Andrea Schmitt
Keyword(s):  
Controlled Trial ◽  
Double Blind ◽  
Acetyl Cysteine

scholarly journals SA19. N-Acetyl-Cysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis

2017 ◽  
Vol 43 (suppl_1) ◽  
pp. S119-S120
Author(s):  
Kim Do ◽  
Larry J. Seidman ◽  
Margot Fournier ◽  
Lijing Xin ◽  
Martine Cleusix ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Early Psychosis ◽  
Double Blind ◽  
Acetyl Cysteine

scholarly journals N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial

2014 ◽  
Vol 49 (6) ◽  
pp. 818-823 ◽  
Author(s):  
A Moslehi ◽  
M Taghizadeh-Ghehi ◽  
K Gholami ◽  
M Hadjibabaie ◽  
Z Jahangard-Rafsanjani ◽  
...  
Keyword(s):  
Oral Mucositis ◽  
Controlled Trial ◽  
Double Blind ◽  
Acetyl Cysteine

N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder—A Double-Blind Randomized Placebo-Controlled Trial

2008 ◽  
Vol 64 (6) ◽  
pp. 468-475 ◽  
Author(s):  
Michael Berk ◽  
David L. Copolov ◽  
Olivia Dean ◽  
Kristy Lu ◽  
Sue Jeavons ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Depressive Symptoms ◽  
Controlled Trial ◽  
Double Blind ◽  
Acetyl Cysteine

scholarly journals Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial

BMC Medicine ◽  
2012 ◽  
Vol 10 (1) ◽  
Author(s):  
Michael Berk ◽  
Olivia M Dean ◽  
Sue M Cotton ◽  
Clarissa S Gama ◽  
Flavio Kapczinski ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Controlled Trial ◽  
Double Blind ◽  
Acetyl Cysteine

A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder

2016 ◽  
Vol 51 (3) ◽  
pp. 241-249 ◽  
Author(s):  
Olivia M Dean ◽  
Kylie M Gray ◽  
Kristi-Ann Villagonzalo ◽  
Seetal Dodd ◽  
Mohammadreza Mohebbi ◽  
...  
Keyword(s):  
Outcome Measures ◽  
Autistic Disorder ◽  
Controlled Trial ◽  
Demographic Data ◽  
Fixed Dose ◽  
Social Responsiveness ◽  
Vineland Adaptive Behavior Scales ◽  
Double Blind ◽  
Significant Difference ◽  
Acetyl Cysteine

Objective: Oxidative stress, inflammation and heavy metals have been implicated in the aetiology of autistic disorder. N-acetyl cysteine has been shown to modulate these pathways, providing a rationale to trial N-acetyl cysteine for autistic disorder. There are now two published pilot studies suggesting efficacy, particularly in symptoms of irritability. This study aimed to explore if N-acetyl cysteine is a useful treatment for autistic disorder. Method: This was a placebo-controlled, randomised clinical trial of 500 mg/day oral N-acetyl cysteine over 6 months, in addition to treatment as usual, in children with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis of autistic disorder. The study was conducted in Victoria, Australia. The primary outcome measures were the Social Responsiveness Scale, Children’s Communication Checklist–Second Edition and the Repetitive Behavior Scale–Revised. Additionally, demographic data, the parent-completed Vineland Adaptive Behavior Scales, Social Communication Questionnaire and clinician-administered Autism Diagnostic Observation Schedule were completed. Results: A total of 102 children were randomised into the study, and 98 (79 male, 19 female; age range: 3.1–9.9 years) attended the baseline appointment with their parent/guardian, forming the Intention to Treat sample. There were no differences between N-acetyl cysteine and placebo-treated groups on any of the outcome measures for either primary or secondary endpoints. There was no significant difference in the number and severity of adverse events between groups. Conclusion: This study failed to demonstrate any benefit of adjunctive N-acetyl cysteine in treating autistic disorder. While this may reflect a true null result, methodological issues particularly the lower dose utilised in this study may be confounders.

scholarly journals Participant Characteristics as Modifiers of Response to N-Acetyl Cysteine (NAC) in Obsessive-Compulsive Disorder

2016 ◽  
Vol 4 (6) ◽  
pp. 1104-1111 ◽  
Author(s):  
Jerome Sarris ◽  
Georgina Oliver ◽  
David A. Camfield ◽  
Olivia M. Dean
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Rating Scale ◽  
Controlled Trial ◽  
Study Endpoint ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Compulsive Disorder ◽  
Modifying Factors ◽  
Scale Scores ◽  
Acetyl Cysteine

We previously reported on a 16-week, double-blind, randomized placebo-controlled trial (RCT) using 3 grams per day of N-acetyl cysteine (NAC) (1.5 grams twice per day) in 44 participants (aged 18–70) with DSM-5-diagnosed obsessive-compulsive disorder (OCD). We now report on an analysis of age, severity and duration of illness, OCD presentation type, baseline anxiety and depression scores, as well as the use of antidepressant medications as potentially modifying factors. Results revealed a significant effect ( p = .037) for younger participants (under mean age of 34) responding to NAC. This remained significant using OCD severity as a covariate ( p = .044). For those under 34 years of age with less than 17 years of OCD duration, this was also significant ( p = .037). Regression analysis within the NAC treatment group also revealed that duration of OCD presentation was a significant predictor of Yale-Brown Obsessive Compulsive Scale (YBOCS) change at study endpoint ( p = .019), whereas baseline Montgomery–Asberg Depression Rating Scale scores were also a trend-level predictor ( p = .060) of YBOCS change in the NAC group.

Sign in / Sign up

Export Citation Format

Share Document